U.S. Securities and Exchange Commission

NewHydrogen continues progress toward lowering the cost of green hydrogen

Retrieved on: 
Wednesday, July 6, 2022 - 8:30am
Hydrogen, Water, PEM, OTC, Solid oxide electrolyzer cell, Incorporation, AEM, Research, Platinum, Electrolysis, GLOBE, COO, Company, Goldman, HER, U.S. Securities and Exchange Commission, Iridium, OER, Oxygen, University of California, Los Angeles, LLC, Environment, Technology, Private Securities Litigation Reform Act, University, Kinetics, UCLA, Sales, Security (finance), Renewable energy, Aluminium, Palladium

SANTA CLARITA, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- NewHydrogen, Inc. (OTC:NEWH), a developer of a green hydrogen generator, today provided an update outlining corporate milestones and the next steps to establish longer-term commercial viability.

Key Points: 
  • NewHydrogen has made significant progress towards its goal of developing technologies that lower the cost of producing green hydrogen, accelerating the timeline for large-scale applications in high growth markets, said Spencer Hall, NewHydrogens COO.
  • The scope of the research was later expanded to include hydrogen evolution reaction (HER) catalysts in addition to oxygen evolution reaction (OER) catalysts.
  • NewHydrogen is developing a breakthrough green hydrogen generator that uses renewable energy to produce low-cost green hydrogen.
  • Unfortunately, hydrogen does not exist in its pure form on Earth so it must be extracted from a source that contains hydrogen.

OpenBet Sports Betting Technology Powers Czech Lottery Company SAZKA a.s.’ Sportsbook Arm, Sazkabet

Retrieved on: 
Wednesday, July 6, 2022 - 9:00am
Sports, Technology, Other Sports, Casino, Gaming, Mobile Entertainment, General Entertainment, Entertainment, Apps, Applications, Internet, Mobile, Wireless, Other Entertainment, Czech Republic, OpenBet, Company, Industry, U.S. Securities and Exchange Commission, Annual report, Czech, Forward-looking statement, Mission statement, Risk, Partnership, Sport, WLA, Technology, Culture, SEC, Solution, Private Securities Litigation Reform Act, NASDAQ, Form 10-K, Scientific Games, Creativity, Security (finance), Science, Online gambling

Sazkabet has entrusted OpenBet to power the next generation of its online and mobile sportsbook offering as part of a new agreement.

Key Points: 
  • Sazkabet has entrusted OpenBet to power the next generation of its online and mobile sportsbook offering as part of a new agreement.
  • OpenBet is fully compliant for the Czech Republic market and will provide a safe and responsible betting experience.
  • SAZKA a.s. is the largest lottery operator in the Czech Republic.
  • OpenBet is the leading provider of sports betting technology, content, and services to lotteries worldwide and this latest agreement ensures seven World Lottery Association (WLA) members are live with its sports betting technology.

DelSiTech and Iveric Bio Enter Exclusive Agreement for Development of Sustained Release Zimura®

Retrieved on: 
Wednesday, July 6, 2022 - 7:00am
C5a, FDA, Patient, European Medicines Agency, MAC, Research, Retina, Marketing, Company, U.S. Securities and Exchange Commission, Forward-looking statement, C5, Epithelium, Business development, EMA, Complement component 5, Food, Retinal pigment epithelium, Geographic atrophy, Private Securities Litigation Reform Act, Technology, RNA, Clinical trial, Organization, Doctor of Philosophy, Nasdaq, Risk, ISEE, Atrophy, AMD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Security (finance), Cell death, Video game console, Pharmaceutical industry, MD

PARSIPPANY, N.J. and TURKU, Finland, July 6, 2022 /PRNewswire/ -- IVERIC bio, Inc. (Nasdaq: ISEE) and DelSiTech Ltd, announced today an exclusive global license agreement providing Iveric Bio with the right to develop and commercialize new formulations of Zimura (avacincaptad pegol) using DelSiTech's silica-based sustained release technology.

Key Points: 
  • PARSIPPANY, N.J. and TURKU, Finland, July 6, 2022 /PRNewswire/ -- IVERIC bio, Inc. (Nasdaq: ISEE) and DelSiTech Ltd, announced today an exclusive global license agreement providing Iveric Bio with the right to develop and commercialize new formulations of Zimura (avacincaptad pegol) using DelSiTech's silica-based sustained release technology.
  • As part of Iveric Bio's lifecycle expansion plan for Zimura, the Company is committed to developing sustained release technologies for the treatment of age-related macular degeneration (AMD).
  • We believe Zimura, which is a chemically synthesized RNA aptamer, is amendable to injectable sustained release formulations."
  • "This agreement underscores our commitment to invest in lifecycle initiatives for Zimura," said Glenn P. Sblendorio, Chief Executive Officer of Iveric Bio.

DelSiTech and Iveric Bio Enter Exclusive Agreement for Development of Sustained Release Zimura®

Retrieved on: 
Wednesday, July 6, 2022 - 7:00am
C5a, FDA, Patient, European Medicines Agency, MAC, Research, Retina, Marketing, Company, U.S. Securities and Exchange Commission, Forward-looking statement, C5, Epithelium, Business development, EMA, Complement component 5, Food, Retinal pigment epithelium, Geographic atrophy, Private Securities Litigation Reform Act, Technology, RNA, Clinical trial, Organization, Doctor of Philosophy, Nasdaq, Risk, ISEE, Atrophy, AMD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Security (finance), Cell death, Video game console, Pharmaceutical industry, MD

PARSIPPANY, N.J. and TURKU, Finland, July 6, 2022 /PRNewswire/ -- IVERIC bio, Inc. (Nasdaq: ISEE) and DelSiTech Ltd, announced today an exclusive global license agreement providing Iveric Bio with the right to develop and commercialize new formulations of Zimura (avacincaptad pegol) using DelSiTech's silica-based sustained release technology.

Key Points: 
  • PARSIPPANY, N.J. and TURKU, Finland, July 6, 2022 /PRNewswire/ -- IVERIC bio, Inc. (Nasdaq: ISEE) and DelSiTech Ltd, announced today an exclusive global license agreement providing Iveric Bio with the right to develop and commercialize new formulations of Zimura (avacincaptad pegol) using DelSiTech's silica-based sustained release technology.
  • As part of Iveric Bio's lifecycle expansion plan for Zimura, the Company is committed to developing sustained release technologies for the treatment of age-related macular degeneration (AMD).
  • We believe Zimura, which is a chemically synthesized RNA aptamer, is amendable to injectable sustained release formulations."
  • "This agreement underscores our commitment to invest in lifecycle initiatives for Zimura," said Glenn P. Sblendorio, Chief Executive Officer of Iveric Bio.

RADA Provides Financial Update

Retrieved on: 
Wednesday, July 6, 2022 - 6:29am
Annual report, RADA, Securities Act of 1933, Electronics, Leonardo DRS, Attention, GLOBE, COVID-19, Sale, Company, U.S. Securities and Exchange Commission, Industry, TASE, Prospectus, FLI, Tax, Risk, Private Securities Litigation Reform Act, Communication, SEC, NASDAQ, Uncertainty, Government, RADA Electronic Industries, Video game, Online gambling, Security (finance)

NETANYA, Israel, July 06, 2022 (GLOBE NEWSWIRE) -- RADA Electronic Industries Ltd. (NASDAQ: RADA, TASE: RADA), a leading global provider of advanced software-defined tactical radars for the maneuver force, today provided a financial update for year 2022.

Key Points: 
  • RADA expects revenue of approximately $22.5 million for the second quarter of 2022;
    In light of the Companys pending merger with Leonardo DRS, RADA is withdrawing its full year 2022 revenue guidance
    NETANYA, Israel, July 06, 2022 (GLOBE NEWSWIRE) -- RADA Electronic Industries Ltd. (NASDAQ: RADA, TASE: RADA), a leading global provider of advanced software-defined tactical radars for the maneuver force, today provided a financial update for year 2022.
  • We strongly believe it is the way forward for RADA and its shareholders it is highly synergistic for both sides.
  • This communication includes certain forward-looking statements and forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995 or the Israeli Securities Law, 1968 (as applicable) (collectively, FLI) to provide RADA Electronic Industries Ltd. (RADA) stockholders with information about RADA.
  • Except to the extent required by law, RADA assumes no obligation to publicly update or revise any FLI, whether as a result of new information, future events or otherwise.

Fluence Announces India Technology Centre, Underscoring Commitment to the Region and Execution of Global Product Strategy

Retrieved on: 
Wednesday, July 6, 2022 - 6:30am
Annual report, TPDDL, Communication, LinkedIn, Securities Act of 1933, Securities Exchange Act of 1934, Engineering, GLOBE, AES, Mitsubishi, Growth, APAC, Ecosystem, U.S. Securities and Exchange Commission, ReNew Power, Marketing communications, Technology, Software, Nasdaq, Tata Power, ReNew, Maintenance, Twitter, Security (finance), Renewable energy, Risk management, Audit, Radiant exposure

The Fluence India Technology Centre supports the execution of the companys global product strategy by growing engineering capabilities and scaling global talent and strengthens Fluences local presence in the country.

Key Points: 
  • The Fluence India Technology Centre supports the execution of the companys global product strategy by growing engineering capabilities and scaling global talent and strengthens Fluences local presence in the country.
  • The Fluence India Technology Centre marks a significant milestone for Fluence, becoming the companys first technology centre based entirely in Asia.
  • Together, the companys technology centre teams support Fluences regionally focused operational model and create a strong foundation for new product introductions and regionalized product support.
  • As the companys largest global technology team, employees at the India Technology Centre are working in the areas of enclosure, battery, and inverter engineering, software quality assurance, product management, and more.

Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-007

Retrieved on: 
Wednesday, July 6, 2022 - 5:40am
Ankylosing spondylitis, OX40L, CDE, AIM, Patient, III, LinkedIn, Atopic dermatitis, Psoriatic arthritis, Adult, OX40, HCM, GLOBE, COVID-19, Population, Cancer, Ligation, U.S. Securities and Exchange Commission, TNFR, Forward-looking statement, National Medical Products Administration, SAN, Therapy, Center, IND, Psoriasis, NMPA, Affibody molecule, HKEX, Silverberg, Sustainable Stock Exchanges Initiative, Private Securities Litigation Reform Act, Safety, Uveitis, Center for Drug Evaluation and Research, Hope, Drug discovery, Protocol, Pharmaceutical industry, Vaccine

Dosing the first participant is an important milestone for the IMG-007 program, said Dr Jonathan Wang, Chairman and Chief Executive Officer of Inmagene.

Key Points: 
  • Dosing the first participant is an important milestone for the IMG-007 program, said Dr Jonathan Wang, Chairman and Chief Executive Officer of Inmagene.
  • We hope the data will help us demonstrate that IMG-007 is one of the strongest OX40 antagonist drug candidates worldwide.
  • It was originally discovered by HUTCHMED, with Inmagene assuming development responsibility at the candidate stage.
  • Inmagene has formed strategic partnerships with multiple partners, such as HUTCHMED and Affibody AB, to develop highly innovative drug candidates.

First Solar Completes Sale of Japan Project Development Platform to PAG Real Assets

Retrieved on: 
Wednesday, July 6, 2022 - 12:00am
Acquisition, Annual report, PV, Climate change, GLOBE, R, Credit, O&M, Sale, APAC, PAG, Analysis, U.S. Securities and Exchange Commission, Forward-looking statement, Terminology, Risk, First Solar, Private equity, Security (finance), Technology, Private Securities Litigation Reform Act, Nasdaq, Financial condition report, Result, FSLR, Maintenance, Real assets, Renewable energy

TEMPE, Ariz. and TOKYO, July 05, 2022 (GLOBE NEWSWIRE) -- First Solar , Inc. (Nasdaq: FSLR) has completed the previously announced sale of a 293-megawatt (MW)DC utility-scale solar project development platform in Japan, to funds managed by PAG Real Assets (PAG).

Key Points: 
  • TEMPE, Ariz. and TOKYO, July 05, 2022 (GLOBE NEWSWIRE) -- First Solar , Inc. (Nasdaq: FSLR) has completed the previously announced sale of a 293-megawatt (MW)DC utility-scale solar project development platform in Japan, to funds managed by PAG Real Assets (PAG).
  • As part of the sale, the majority of First Solar project development employees in Japan have joined PAG.
  • First Solar had also previously announced that it had entered into a definitive agreement pursuant to which PAG will acquire from First Solar its solar operations and maintenance (O&M) platform with approximately 665 MWDC under management, in Japan.
  • Founded in 1997 as Secured Capital Japan, PAG Real Assets has invested $32 billion across more than 7,000 properties across the Asia-Pacific region.

Additional Grayscale® Investment Products Become SEC Reporting Companies

Retrieved on: 
Tuesday, July 5, 2022 - 10:55pm
Stellar, Bitcoin, Bitcoin Cash, Ethereum, Ethereum Classic, Litecoin, OTCQX, Securities Exchange Act of 1934, Trust, Securities Act of 1933, Investment, Trust law, GLOBE, Grayscale, Sale, Exchange, Registration statement, U.S. Securities and Exchange Commission, Future Forward Party, ETF, LLC, Mission statement, SEC, Lovell Minnick Partners, Family, Security (finance)

The Trusts join the firms existing lineup of investment products that are SEC reporting companies: Grayscale Bitcoin Cash Trust , Grayscale Ethereum Classic Trust , Grayscale Litecoin Trust , Grayscale Bitcoin Trust , Grayscale Ethereum Trust , and Grayscale Digital Large Cap Fund .

Key Points: 
  • The Trusts join the firms existing lineup of investment products that are SEC reporting companies: Grayscale Bitcoin Cash Trust , Grayscale Ethereum Classic Trust , Grayscale Litecoin Trust , Grayscale Bitcoin Trust , Grayscale Ethereum Trust , and Grayscale Digital Large Cap Fund .
  • With these new additions, nine of Grayscales digital currency investment products are now SEC reporting companies.
  • Grayscale enables investors to access the digital economy through a family of secure, regulated, and future-forward investment products.
  • Grayscale products are distributed by Genesis Global Trading, Inc. (Member FINRA/SIPC, MSRB Registered) or Foreside Fund Services, LLC.

SCWorx Announces Common Stock Purchase Agreement with Institutional Investor

Retrieved on: 
Tuesday, July 5, 2022 - 10:14pm
Institution, Hannibal, Annual report, CEO, MMIS, EMR, File, GLOBE, Intelligence, Growth, Sale, Company, U.S. Securities and Exchange Commission, Prospectus, Health, Software as a service, Benchmarking, Asset purchase agreement, Contract, Institutional investor, Private Securities Litigation Reform Act, RFP, Machine learning, Bill, Solution, News, Investor, Security (finance), Hospital

New York, NY, July 05, 2022 (GLOBE NEWSWIRE) -- SCWorx Corp., a Delaware corporation (the Company), announced that it has entered into a common stock purchase agreement (the Purchase Agreement) with an institutional investor (the Institutional Investor or Investor).

Key Points: 
  • New York, NY, July 05, 2022 (GLOBE NEWSWIRE) -- SCWorx Corp., a Delaware corporation (the Company), announced that it has entered into a common stock purchase agreement (the Purchase Agreement) with an institutional investor (the Institutional Investor or Investor).
  • Under the terms and subject to the conditions of the Purchase Agreement, SCWorx will have the right, but not the obligation, to issue and sell to the Investor up to $5 million of SCWorx common stock from time-to-time over the approximately 24-month term of the Purchase Agreement.
  • Under the terms of the Purchase Agreement, SCWorx has the right, but not the obligation, to sell to the Investor up to $5 million of its common stock, subject to certain conditions.
  • As consideration for the Institutional Investors commitment to purchase shares of SCWorxs common stock upon the terms and conditions set forth in the Purchase Agreement, SCWorx will issue 277,778 shares of its common stock to the Investor.